AEterna Zentaris Inc. (NASDAQ:AEZS) shares have been given an average broker rating of 1.25 by Wall Street analysts covering the stock. This number, which is calculated by Zacks Research, is based on the 4 research brokerages …
Finally, Maxim Group lifted their price target on shares of AEterna Zentaris from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Tuesday, January 17th. AEterna Zentaris (NASDAQ:AEZS) traded up 1.64% during trading …
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: View the entire Zacks #1 Rank List. AETERNA ZENTARIS INC (AEZS): Free Stock Analysis Report AMETEK INC NEW (AME): Free Stock Analysis Report ARENA …
Aeterna Zentaris Inc (NASDAQ:AEZS) soared today, with its share price jumping 35 cents to hit $2.90 at the market close – more than 13 percent higher. In after-hours trading, the pharmaceutical company’s stock is up an additional 6.9 percent.
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the “Company”) announced today ... sell up to a maximum of 3,000,000 common shares through ATM issuances on the NASDAQ Stock Market, up to an aggregate amount of $9.0 …
Connecture Incorporated (CNXR) had a gap up of 0.2196 pts or 6.15 pct above its previous close of $3.57. The company traded at $3.58 + 0.01 (0.28 pct). Imprimis Pharmaceuticals Incorporated (IMMY) had a gap up of (0.07) pts or -1.04 pct …
Aeterna says AEZS-108 does less damage to healthy tissue than existing treatments. Disappointing trial results for another cancer drug, perifosine, have weighed heavily on Aeterna's stock this year, and in October it consolidated its …
The stock is up 37.83% or $1.01 following the news, hitting $3.68 per share. About 900,211 shares traded hands. AEZS
(RTTNews.com) - Aeterna Zentaris Inc. ( AEZS) (AEZS.TO) is gearing up to file a new drug application ... CBIO closed Thursday's trading at $9.24, down 12.08%. In after-hours, the stock was up 7.68% to $9.95. Genmab A/S' …
The company had no specific news. Aeterna Zentaris Inc. (NASDAQ: AEZS) dropped about 36% on Thursday to post a new 52-week low of $2.35 after closing at $3.65 on Wednesday. The stock’s 52-week high is $5.59. Volume was about …